Paxman AB
The answer first
Does Paxman beat the market?
No, Paxman has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 48% of Nordic stocks
- Quality48
- Value16
- Trend89
No. 64 of 195 in healthcare
Max for seven days
Follow Paxman with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Paxman
Your first answer is free, no account needed.
Do you own Paxman, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Paxman and a few more. Free, no card.
Super Stock+44.6%In short
- Paxman has risen 7.1% over the past year, including dividends.
- Overall, Paxman ranks better than 48% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 64.0%. The price is 20.8% below its peak now.
What do analysts think of Paxman?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 48% of Nordic stocks.
No. 64 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 134 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.03
- Asset turnoverSales divided by everything the company owns0.75
- Return on equityProfit divided by equity−1.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 112 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.6
- P/SPrice divided by sales4.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 26 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+20.7%
- 6 months+28.7%
- 9 months+30.2%
- 12 months+7.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Paxman
5 funds we follow own Paxman. The share is how much of the fund the stock makes up.
- Sweden5
From the funds' latest known holdings.
About Paxman
Paxman AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 150 employees.
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.


See the full analysis of Paxman.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card